Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.
about
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseasesNarcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritisInfluenza vaccination in immunocompromised patients: efficacy and safety.Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis.High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.The effect of rituximab on vaccine responses in patients with immune thrombocytopenia2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Vaccinations for rheumatoid arthritis.Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyA literature review on the patients with autoimmune diseases following vaccination against infections.Rituximab-treated patients have a poor response to influenza vaccinationImmunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis.Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.Vaccination of patients with autoimmune inflammatory rheumatic diseases.A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia.Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis.H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production.Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis.Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.When treating rheumatoid arthritis be vigilant for influenza (& pneumonia): Don't ignore, don't neglect.Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
P2860
Q26825440-30BE7388-76A5-4958-B70C-0FCAE257CA0BQ30356910-24427EEE-B3C6-4893-BBFC-B4F84A73FDADQ30357450-7FC9EDAC-3F7E-41C3-B51B-C8DE15030EBDQ30358640-B1875882-12C6-47C8-977B-F0C7243385FAQ30360610-9D9A41C9-F07D-4D3E-9BDD-B334E643A8C3Q30413413-01179471-2BA2-4589-A206-12DE626582FCQ30419842-E551B3E6-CEBF-4974-BEBC-987FE09F1ECDQ30420493-A62BB6AE-F318-4632-9A7F-E122D72F49DDQ30420964-18D93A56-8462-49EC-81CF-B3EC5D5BA355Q30432642-869A3E6D-D451-4395-9CD8-889F4AAE19AFQ33409067-08845C85-F9C2-4DBD-A6C5-9A3F18CFB157Q34390072-030B9024-844C-42E8-B2DE-F96F2A90F618Q34424563-EB1E10E1-61F4-4686-9641-D99BA27951DCQ35782767-DAE32908-1BC7-445A-9FB4-9660429D6A02Q36255747-664B023B-BC8A-447E-B965-9F8BE6AE18B1Q36589247-01947378-0FB9-4208-AE7F-20DB471E01F8Q36644797-5FF5AB0F-386E-41D8-98D5-7951BE3D8FA9Q36679769-3B703FA2-90F3-4E37-AF21-3ACD3B8E0D4EQ38171461-E644D5F1-4198-4C26-AC9F-2F93A8B6FD6FQ38285275-FF845FFF-3E5E-4B77-8650-6B54978894ABQ39013188-632DACFB-C2E7-455D-BABD-FE14DF01A4F2Q39675557-3DBBE38D-F808-44E6-8798-5B7D321E22A2Q40061605-765A31A0-C195-4054-9BFE-8E0A61946069Q41912227-0DE15D79-76E8-4921-BFE4-0CEBBF434AA6Q41926425-B8591B72-E968-43E6-92B2-F654DEF9AE12Q42252304-3D4B137D-F4AF-4830-B692-BB3FD1F8444DQ46745289-1ACD73A6-2183-44AA-88E4-8F5884BD5C34Q54249618-4A7388E0-820C-4DFC-A827-8316326EED9B
P2860
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of synthetic and biolog ...... l-cohort, single-center study.
@ast
Impact of synthetic and biolog ...... l-cohort, single-center study.
@en
type
label
Impact of synthetic and biolog ...... l-cohort, single-center study.
@ast
Impact of synthetic and biolog ...... l-cohort, single-center study.
@en
prefLabel
Impact of synthetic and biolog ...... l-cohort, single-center study.
@ast
Impact of synthetic and biolog ...... l-cohort, single-center study.
@en
P2093
P2860
P356
P1476
Impact of synthetic and biolog ...... l-cohort, single-center study.
@en
P2093
Camillo Ribi
Christophe Combescure
H1N1 Study Group
Jörg D Seebach
Klara Posfay-Barbe
Laurent Kaiser
Michael Bel
Pierre-André Guerne
Sara Meier
Stéphane Grillet
P2860
P304
P356
10.1002/ART.30325
P577
2011-06-01T00:00:00Z